Curanex Pharmaceuticals (CURX) Non-Current Assets (2025 - 2026)
Curanex Pharmaceuticals' (CURX) quarterly Non-Current Assets came in at $280939.0 in Q2 2026, up 270.45% on a YoY basis from $75837.0 in Q2 2025, and down 20.33% quarter-over-quarter from $352616.0 in Q4 2025.
Powered by 
Analysis
Curanex Pharmaceuticals (CURX) Non-Current Assets (2025 - 2026) Analysis & Trends
Curanex Pharmaceuticals (CURX) has reported Non-Current Assets for 2 consecutive years, with $280939.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets rose 270.45% year-over-year to $280939.0; the trailing twelve-month figure through Jun 2026 stood at $769790.0 (changed N/A YoY), and the FY2025 full-year result was $352616.0, changed N/A from the prior year.
- Non-Current Assets fell to $280939.0 in Q2 2026 per CURX's latest filing, from $352616.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $352616.0 in Q4 2025 and bottomed at $60398.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 294.93 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1.85 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 3.74 Bn |
| 10 | Curanex Pharmaceuticals | 5.97 Mn | 3.03 Mn | - | 280,939.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 280,939.00 |
| Dec 31, 2025 | 352,616.00 |
| Sep 30, 2025 | 60,398.00 |
| Jun 30, 2025 | 75,837.00 |